WKB Lawyers advised Blirt S.A. shareholder’s on sale of a 96% share stake to QIAGEN an international biotech company.
WKB provided the sellers with comprehensive legal support in structuring the transaction and negotiating the transaction documents.
BLIRT is a company with many years of experience specialising in industrial-scale production of high-quality recombinant proteins. The firm also produces kits for the isolation of DNA and RNA and reagents for reverse transcription and Real-Time PCR, which have gained broad interest in the B2B sector and are sold to researchers via a global network of distributors.
QIAGEN N.V. is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights.
Jakub Jędrzejak (partner) led the team’s work, whose key members were Tomasz Maślak (managing associate) and Joanna Ksepko (associate) with the support from Marta Midloch (partner) and Anna Matsiyeuskaya (associate).